Restricted accessResearch articleFirst published online 2019-12
Glycomics for Type 2 Diabetes Biomarker Discovery: Promise of Immunoglobulin G Subclass-Specific Fragment Crystallizable N-glycosylation in the Uyghur Population
Aberrant immunoglobulin G (IgG) N-glycosylation offers new prospects to detect changes in cell metabolism and by extension, for biomarker discovery in type 2 diabetes mellitus (T2DM). However, past studies did not analyze the individual IgG subclasses in relation to T2DM pathophysiology. We report here original findings through a comparison of the IgG subclass-specific fragment crystallizable (Fc) glycan biosignatures in 115 T2DM patients with 122 healthy controls within the Uyghur population in China. IgG Fc glycosylation profiles were analyzed using nano-liquid chromatography–mass spectrometry to exclude changes attributed to fragment antigen binding N-glycosylation. After correction for clinical covariates, 27 directly measured and 4 derived glycan traits of the IgG subclass-specific N-glycopeptides were significantly associated with T2DM. Furthermore, we observed in T2DM a decrease in bisecting N-acetylglucosamine of IgG2 and agalactosylation of IgG4, and an increase in sialylation of IgG4 and digalactosylation of IgG2. Classification model based on IgG subclass-specific N-glycan traits was able to distinguish patients with T2DM from controls with an area under the receiver operating characteristic curve of 0.927 (95% confidence interval 0.894–0.960, p < 0.001). In conclusion, a robust association between the IgG subclass-specific Fc N-glycomes and T2DM was observed in the Uyghur population sample in China, suggesting a potential for the IgG Fc glycosylation as a biomarker candidate for type 2 diabetes. The integration of glycomics with other system science biomarkers might offer further hope for innovation in diagnosis and treatment of T2DM in the future. Finally, it is noteworthy that “Population Glycomics” is an emerging approach to biomarker discovery for common complex diseases.
Get full access to this article
View all access options for this article.
References
1.
AduaE, MemarianE, RussellA, et al. (2019). High throughput profiling of whole plasma N-glycans in type II diabetes mellitus patients and healthy individuals: A perspective from a Ghanaian population. Arch Biochem Biophys, 661, 10–21.
2.
AlbertiKG, and ZimmetPZ. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 15, 539–553.
3.
American Diabetes Association. (2012). Diagnosis and classification of diabetes mellitus. Diabetes Care 35 Suppl, 1, S64–S71.
4.
BakovicMP, SelmanMH, HoffmannM, et al. (2013). High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res, 12, 821–831.
5.
BenjaminiY, and HochbergY. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc, 57, 289–300.
6.
BondtA, SelmanMH, DeelderAM, et al. (2013). Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res, 12, 4522–4531.
7.
BondtA, WuhrerM, KuijperTM, HazesJM, and DolhainRJ. (2016). Fab glycosylation of immunoglobulin G does not associate with improvement of rheumatoid arthritis during pregnancy. Arthritis Res Ther, 18, 274.
8.
ChenG, WangY, QinX, et al. (2013). Change in IgG1 Fc N-linked glycosylation in human lung cancer: Age- and sex-related diagnostic potential. Electrophoresis, 34, 2407–2416.
9.
CollinM, and EhlersM. (2013). The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies. Exp Dermatol, 22, 511–514.
10.
FukuiM, TanakaM, TodaH, et al. (2011). Risk factors for development of diabetes mellitus, hypertension and dyslipidemia. Diabetes Res Clin Pract, 94, e15–e18.
11.
GaoQ, DolikunM, StambukJ, et al. (2017). Immunoglobulin G N-glycans as potential postgenomic biomarkers for hypertension in the Kazakh population. Omics, 21, 380–389.
12.
GeS, WangY, SongM, et al. (2018) Type 2 diabetes mellitus: Integrative analysis of multiomics data for biomarker discovery. OMICS, 22, 514–523.
13.
GokmenSS, KilicliG, OzcelikF, TureM, and GulenS. (2002). Association between serum total and lipid-bound sialic acid concentration and the severity of coronary atherosclerosis. J Lab Clin Med, 140, 110–118.
14.
GornikO, PavicT, and LaucG. (2012). Alternative glycosylation modulates function of IgG and other proteins - implications on evolution and disease. Biochim Biophys Acta, 1820, 1318–1326.
15.
GornikO, WagnerJ, PucicM, KnezevicA, RedzicI, and LaucG. (2009). Stability of N-glycan profiles in human plasma. Glycobiology, 19, 1547–1553.
16.
GudeljI, LaucG, and PezerM. (2018). Immunoglobulin G glycosylation in aging and diseases. Cell Immunol, 333, 65–79.
17.
HastieT, TibshiraniR, and FriedmanJ. (2008) The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2nd ed. Stanford, CA: Springer.
18.
HuC, and JiaW. (2018). Diabetes in China: Epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes, 67, 3–11.
19.
Inayat urR, MalikSA, BashirM, KhanR, and IqbalM. (2009). Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment. Phytomedicine, 16, 401–405.
ItohN, SakaueS, NakagawaH, et al. (2007). Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes. Am J Physiol Endocrinol Metab, 293, E1069–E1077.
22.
JennrichRI, and SampsonPF. (1968). Application of stepwise regression to non-linear estimation. Technometrics, 10, 10.
23.
JohnsonWE, LiC, and RabinovicA. (2007). Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics, 8, 118–127.
24.
JonesMC, and PewseyA. (2009). Bayesian lasso regression. Biometrika, 96, 835–845.
25.
KanekoY, NimmerjahnF, and RavetchJV. (2006). Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313, 670–673.
26.
KarstenCM, PandeyMK, FiggeJ, et al. (2012). Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med, 18, 1401–1406.
27.
KeserT, GornikI, VuckovicF, et al. (2017b). Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes. Diabetologia, 60, 2352–2360.
28.
KeserT, VuckovicF, BarriosC, et al. (2017a). Effects of statins on the immunoglobulin G glycome. Biochim Biophys Acta Gen Subj 1861 (5 Pt A), 1152–1158.
29.
KhaliliP, SundstromJ, JendleJ, LundinF, JungnerI, and NilssonPM. (2014). Sialic acid and incidence of hospitalization for diabetes and its complications during 40-years of follow-up in a large cohort: The Varmland survey. Prim Care Diabetes, 8, 352–357.
30.
KizukaY, and TaniguchiN. (2016). Enzymes for N-Glycan Branching and Their Genetic and Nongenetic Regulation in Cancer. Biomolecules, 6, 25.
31.
KnezevicA, PolasekO, GornikO, et al. (2009). Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res, 8, 694–701.
32.
LaucG, PezerM, RudanI, and CampbellH. (2016). Mechanisms of disease: The human N-glycome. Biochim Biophys Acta, 1860, 1574–1582.
33.
LemmersRFH, VilajM, UrdaD, et al. (2017). IgG glycan patterns are associated with type 2 diabetes in independent European populations. Biochim Biophys Acta, 1861, 2240–2249.
34.
LiuD, ZhaoZY, WangAX, et al. (2018a). Ischemic stroke is associated with the pro-inflammatory potential of N-glycosylated immunoglobulin G. J Neuroinflammation, 15, 123.
35.
LiuJN, DolikunM, StambukJ, et al. (2018b). The association between subclass-specific IgG Fc N-glycosylation profiles and hypertension in the Uygur, Kazak, Kirgiz, and Tajik populations. J Hum Hypertens, 32, 555–563.
36.
LiuLS, and Joint Committee for Guideline Revision. (2019). 2018 Chinese Guidelines for Prevention and Treatment of Hypertension—A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol, 16, 182–241.
37.
LuJP, KnezevicA, WangYX, et al. (2011). Screening novel biomarkers for metabolic syndrome by profiling human plasma N-glycans in Chinese Han and Croatian populations. J Proteome Res, 10, 4959–4969.
38.
MehtaNN. (2012). Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes mellitus. Circ Cardiovasc Genet, 5, 708–710.
39.
MenniC, KeserT, ManginoM, et al. (2013). Glycosylation of immunoglobulin G: Role of genetic and epigenetic influences. PLoS One, 8, e82558.
40.
MihaiS, and NimmerjahnF. (2013). The role of Fc receptors and complement in autoimmunity. Autoimmun Rev, 12, 657–660.
41.
PucicM, KnezevicA, VidicJ, et al. (2011). High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics, 10, M111.010090.
42.
RookGA, SteeleJ, BrealeyR, et al. (1991). Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun, 4, 779–794.
43.
RussellAC, SimurinaM, GarciaMT, et al. (2017). The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease. Glycobiology, 27, 501–510.
44.
SchwabI, and NimmerjahnF. (2013). Intravenous immunoglobulin therapy: How does IgG modulate the immune system?. Nat Rev Immunol, 13, 176–189.
45.
SelmanMH, DerksRJ, BondtA, et al. (2012). Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. J Proteomics, 75, 1318–1329.
46.
ShinkawaT, NakamuraK, YamaneN, et al. (2003). The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem, 278, 3466–3473.
47.
SimurinaM, de HaanN, VuckovicF, et al. (2018). Glycosylation of immunoglobulin G associates with clinical features of inflammatory bowel diseases. Gastroenterology, 154, 1320–1333.e1310.
TaoY, MaoX, XieZ, et al. (2008). The prevalence of type 2 diabetes and hypertension in Uygur and Kazak populations. Cardiovasc Toxicol, 8, 155–159.
50.
TestaR, VanhoorenV, BonfigliAR, et al. (2015). N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One, 10, e0119983.
51.
VarkiA. (1993). Biological roles of oligosaccharides: All of the theories are correct. Glycobiology, 3, 97.
52.
VuckovicF, TheodoratouE, ThaciK, et al. (2016). IgG Glycome in Colorectal Cancer. Clin Cancer Res, 22, 3078–3086.
53.
WangL, GaoP, ZhangM, et al. (2017). Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA, 317, 2515–2523.
54.
WangYX, KlaricL, YuXW, et al. (2016). The Association Between Glycosylation of Immunoglobulin G and Hypertension: A Multiple Ethnic Cross-Sectional Study. Medicine (Baltimore), 95, e3379.
55.
ZhaoFF, DolikunM, WangYX, et al. (2016). The Uyghur population and genetic susceptibility to type 2 diabetes: Potential role for variants in CAPN10, APM1 and FUT6 genes. J Cell Mol Med, 20, 2138–2147.
56.
ZhuJR, GaoRL, ZhaoSP, et al. (2016). Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (Revised Edition 2016). J Chinese Circulation, 31, 937–953 (in Chinese).
57.
ZouG, OchiaiH, HuangW, YangQ, LiC, and WangLX. (2011). Chemoenzymatic synthesis and Fcgamma receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcgammaIIIa receptor. J Am Chem Soc, 133, 18975–18991.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
